Trial Profile
Evaluation of improvement effects of angiotensin II receptor blockers on glycemic and lipid metabolism in renal transplant patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary) ; Telmisartan (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- 20 Aug 2012 Actual initiation date (1 Feb 2011) added as reported by University Hospital Medical Information Network - Japan
- 20 Aug 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan
- 28 Feb 2011 New trial record